The world's first bivalent mRNA vaccine candidate against respiratory syncytial virus, or RSV, kicked off Phase I clinical trial in China on Wednesday, as an adult received a shot at a clinical ...

Regulatory authorities in the US are investigating a possible link between the new Pfizer/BioNTech bivalent COVID-19 booster vaccine and strokes in people aged 65 or over, but still recommend the ...

Moderna has reported preliminary clinical results with a bivalent version of its COVID-19 vaccine that combines its original version with another targeting the Beta variant, and seems to offer ...

The RSVPreF vaccine is safe and demonstrates immunobridging to efficacy among adults aged 18 to 59 who are at high risk for severe RSV disease.

SINGAPORE: With 386,000 bivalent COVID-19 vaccine doses issued since their introduction in mid-October, the Government hopes to encourage more sign-ups - especially among the elderly - with the ...

Following a UNICEF order worth ₹127 crore, Panacea Biotec shares increased 5% to ₹456.25. The stock has seen substantial ...

"Bivalent mRNA booster vaccination in adults aged 65 years or older is an effective and essential tool to reduce their risk of hospitalisation and death due to Covid-19.

Panacea Biotec's shares rose 5% as the company received a Letter of Award from UNICEF for supplying 115 million doses of its ...

Such a contract symbolizes Panacea Biotec's continued commitment toward global health by contributing its share of the fight ...

Panacea Biotec hit an upper circuit of 5% at Rs 455.70 after the company received a letter of award (LoA) from the United Nations International Children's Emergency Fund (UNICEF) for supply its ...